Share this Page:
In an interview with OncLive at the 2016 Kidney Cancer Symposium, Dr Neeraj Agarwal, who is director of the Genitourinary Oncology Program at Huntsman Cancer Institute of the University of Utah, discussed the concerns with inadequate reporting of autoimmune side effects associated with PD-1 inhibitors in renal cell carcinoma (RCC).
Dr Agarwal explained that there has been a trend of under-reporting and under-emphasising the side effects associated with PD-1 inhibitors during the treatment of people with RCC. According to Dr Agarwal, these side effects must be recognised, reported, and treated early because more common side effects, like diarrhoea and fatigue, can potentially evolve to more severe and potentially life-threatening conditions, such as fulminant colitis and myocarditis.
